Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.43 |
| ▸ | NOS3 | P29474 | 10/20 | 0.43 |
| ▸ | NOS1 | P29475 | 8/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4437267 | 0.97 | NOS2 (0.42) | NOS2NOS3NOS1BACE1MAPT | |
| SCHEMBL8344113 | 0.79 | KDM4E (0.54) | NOS2NOS3NOS1MAPTTDP1 | |
| SCHEMBL3673476 | 0.79 | NOS2 (0.48) | NOS2NOS3NOS1BACE1PRMT5 | |
| SCHEMBL2955353 | 0.79 | TDP1 (0.43) | NOS2NOS3NOS1BACE1MAPT | |
| SCHEMBL23860779 | 0.75 | NOS3 (0.38) | NOS2NOS3NOS1MAPTTERT | |
| SCHEMBL3637109 | 0.75 | NOS3 (0.41) | NOS2NOS3NOS1BACE1MAPT | |
| SCHEMBL30689574 | 0.75 | NOS3 (0.38) | NOS2NOS3NOS1MAPTTERT | |
| SCHEMBL14385061 | 0.72 | NOS3 (0.39) | NOS2NOS3NOS1BACE1MAPT | |
| SCHEMBL24227068 | 0.72 | NOS2 (0.45) | NOS2NOS3NOS1BACE1PRMT5 | |
| SCHEMBL22063592 | 0.72 | REN (0.47) | NOS2NOS3NOS1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598048-B1 | Composition for coloring of keratin fibres | KPSS KAO GMBH (DE) | 2008-08-13 | — | — | EP | claimed |
| CN-1518543-A | Pyrazole derivatives and their use as protein kinase inhibitors | �Ʒ� | 2004-08-04 | — | — | CN | claimed |
| JP-2019576-A | — | — | None | — | — | JP | disclosed |
| CN-110325530-B | GLP-1 receptor agonists and uses thereof | 辉瑞大药厂 | 2022-01-11 | — | — | CN | disclosed |
| CN-113874019-A | Combinations comprising benzodioxoles as GLP-1R agonists for the treatment of NASH/NAFLD and related diseases | 辉瑞大药厂 | 2021-12-31 | — | — | CN | disclosed |
| EP-3806955-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-112566637-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-108066340-B | Pharmaceutical composition | 中国科学院化学研究所 | 2020-10-27 | — | — | CN | disclosed |
| CN-108069964-B | Macrocyclic compounds and pharmaceutical compositions | 北京师范大学 | 2020-07-07 | — | — | CN | disclosed |
| CN-109867707-A | The method of atriphos is extracted from the solution containing atriphos | 中国科学院化学研究所 | 2019-06-11 | — | — | CN | disclosed |
| CN-108069964-A | Macrocyclic compound and pharmaceutical composition | 北京师范大学 | 2018-05-25 | — | — | CN | disclosed |
| CN-108066340-A | Pharmaceutical composition | 中国科学院化学研究所 | 2018-05-25 | — | — | CN | disclosed |
| CN-108066341-A | Purposes of the compound in anticancer drug is prepared | 中国科学院化学研究所 | 2018-05-25 | — | — | CN | disclosed |
| CN-1518543-A | Pyrazole derivatives and their use as protein kinase inhibitors | �Ʒ� | 2004-08-04 | — | — | CN | disclosed |
| US-4931487-A | Chain extenders for polyurethanes | DOW CHEMICAL COMPANY | 1990-06-05 | — | — | US | disclosed |
| JP-H0219576-A | DYEING COMPOSITION FOR KERATINOUS FIBER | KAO CORP | 1990-01-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | NOS2 3753/4885NOS3 3211/4885NOS1 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.